Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae
- PMID: 20194704
- PMCID: PMC2863635
- DOI: 10.1128/AAC.00019-10
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae
Abstract
We compared the affinities of ceftaroline for all penicillin-binding proteins (PBPs) with those of ceftriaxone and cefotaxime in 6 Staphylococcus aureus and 7 Streptococcus pneumoniae isolates with various resistance phenotypes. Ceftaroline MICs were <or=1 microg/ml against all S. aureus isolates and were <or=0.25 microg/ml for 4 of 7 isolates of S. pneumoniae. Ceftaroline affinities for penicillin-susceptible S. pneumoniae strains were in the order PBP2X and -3 > PBP1A, -1B, and -2A > PBP2B, and ceftaroline had >or=4-fold higher 50% inhibitory concentrations (IC(50)s) (0.1 to 4 microg/ml) for PBP2X, -2A, -2B, and -3 than those for the other cephalosporins tested. Among 3 penicillin-resistant S. pneumoniae strains, ceftaroline had a high affinity for PBP2X (IC(50), 0.1 to 1 microg/ml), a primary target for cephalosporin PBP binding activity, and high affinities for PBP2B (IC(50), 0.5 to 4 microg/ml) and PBP1A (IC(50), 0.125 to 0.25 microg/ml) as well, both of which are also known as major targets for PBP binding activity of cephalosporins. Ceftaroline PBP affinities in methicillin-susceptible S. aureus strains were greater than or equal to those of the 3 other beta-lactams tested. Ceftaroline bound to PBP2a in methicillin-resistant S. aureus (IC(50), 0.01 to 1 microg/ml) with up to 256-fold-higher affinity than those of other agents. Ceftaroline demonstrated very good PBP affinity against all S. aureus and S. pneumoniae strains tested, including resistant isolates.
Figures
Similar articles
-
Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.J Antimicrob Chemother. 2010 Apr;65(4):713-6. doi: 10.1093/jac/dkp503. Epub 2010 Jan 22. J Antimicrob Chemother. 2010. PMID: 20097788
-
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.Antimicrob Agents Chemother. 2009 Feb;53(2):552-6. doi: 10.1128/AAC.01324-08. Epub 2008 Nov 17. Antimicrob Agents Chemother. 2009. PMID: 19015339 Free PMC article.
-
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).Clin Infect Dis. 2012 Sep;55 Suppl 3:S206-14. doi: 10.1093/cid/cis563. Clin Infect Dis. 2012. PMID: 22903953 Review.
-
[Evaluation of penicillin-binding protein genotypes in penicillin susceptible and resistant Streptococcus pneumoniae isolates].Mikrobiyol Bul. 2012 Apr;46(2):190-201. Mikrobiyol Bul. 2012. PMID: 22639308 Turkish.
-
Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.Drugs. 2009;69(7):809-31. doi: 10.2165/00003495-200969070-00003. Drugs. 2009. PMID: 19441869 Review.
Cited by
-
Identification of 5-(Aryl/Heteroaryl)amino-4-quinolones as Potent Membrane-Disrupting Agents to Combat Antibiotic-Resistant Gram-Positive Bacteria.J Med Chem. 2022 Oct 27;65(20):13910-13934. doi: 10.1021/acs.jmedchem.2c01151. Epub 2022 Oct 11. J Med Chem. 2022. PMID: 36219779 Free PMC article.
-
Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.Drugs. 2016 Nov;76(17):1659-1674. doi: 10.1007/s40265-016-0654-4. Drugs. 2016. PMID: 27766567 Review.
-
Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.Clin Microbiol Infect. 2021 Jun;27(6):910.e1-910.e8. doi: 10.1016/j.cmi.2020.08.025. Epub 2020 Aug 28. Clin Microbiol Infect. 2021. PMID: 32866650 Free PMC article.
-
Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA).Clin Med Rev Ther. 2011 Feb 10;3:a2466. doi: 10.4137/CMRT.S1637. Clin Med Rev Ther. 2011. PMID: 21785568 Free PMC article.
-
In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14. Antimicrob Agents Chemother. 2011. PMID: 21402844 Free PMC article.
References
-
- Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):16-23. - PubMed
-
- Bozdogan, B., D. Esel, C. Whitener, F. A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868. - PubMed
-
- Centers for Disease Control and Prevention. 2002. Vancomycin-resistant Staphylococcus aureus—Pennsylvania, 2002. MMWR Morb. Mortal. Wkly. Rep. 51:902. http://www.cdc.gov/mmwr//preview/mmwrhtml/mm5126a1.htm. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Chemical Information
Medical
Research Materials
Miscellaneous